Revolution Medicines RVMD

Reference table

1. What they actually have — the pipeline, and what the dataset does and does not contain

What the company describes. Revolution Medicines is a precision-oncology company targeting RAS-driven cancers, headquartered in Redwood City, California, with 883 employees and CEO Mark A. Goldsmith. The pipeline described in the dataset:

The critical structural point. This is a pathway franchise, not a single asset. Multiple ON-state inhibitors across multiple RAS mutations, plus upstream (SOS1, SHP2) and downstream (mTORC1) programmes. That is what justifies the Exponential score of 9 — and it is also what makes a class-wide safety signal an existential rather than a partial risk.

What the dataset does NOT contain, stated plainly:

• No clinical trial data. There is no trials file for this ticker. Every efficacy figure in this dive is a citation of a tracked thinker's dated statement, explicitly labelled as such, and is not verified trial data.
• No regulatory status. The dataset does not confirm whether daraxonrasib has been approved. A tracked claim dated 2026-06-12 said approval was expected "almost any day now", and consensus models $101.67M of FY2026 revenue on 15 analysts, which implies the Street models a 2026 launch — but the file contains no approval confirmation and we are not going to assert one.
• No product-level revenue disclosure. seg_prod contains only historical collaboration revenue (FY2020-FY2022, $29-43M a year from the Sanofi relationship), and seg_geo is empty — the company does not report geographic segments.

2. The financials — a company spending like a launch is coming

R&D has compounded 57.2% a year from $253.07M (FY2022) to $978.68M (FY2025) — a 3.87x increase in three years. The Sanofi collaboration revenue that used to appear ($29-43M a year) has gone to zero from FY2024.

The quarterly burn series is the most important table in this dive:

Nine consecutive quarters of rising losses, with no deceleration anywhere. Q1 2026's loss is 3.9x Q1 2024's. Year over year, Q1 2026 R&D rose 67.2% and SG&A rose 189.2% — from $35.01M to $101.25M.

That SG&A number is the single most informative operational datum in the file. A company does not nearly triple its selling, general and administrative spend in twelve months unless it is building a commercial organisation. It is the strongest available evidence in this dataset that a launch is imminent or underway — stronger, in an evidentiary sense, than any commentary, because it is an audited cash cost the company has actually incurred.

3. Runway — the arithmetic, and the seven-month hole in it

What we can see (all as of 2025-12-31):

• Cash and equivalents $383.75M
• Short-term investments $1.642B
• Total liquidity $2.026B
• Total current assets $2.075B, total current liabilities $290.42M → current ratio 6.80x
• Total debt $158.70M (long-term $142.23M); debt-to-equity 0.29x
• Equity $1.631B; accumulated deficit $2.869B

The runway calculation, with every assumption labelled:

• Q1 2026 net loss: $453.82M.
• FY2025 stock-based compensation was $118.39M, or roughly $29.6M a quarter — a non-cash charge to add back.
• Implied cash burn ≈ $424M a quarter, or roughly $1.70B annualised.
• $2.026B ÷ $424M ≈ 4.8 quarters — approximately twelve months of runway from 2025-12-31, i.e. to roughly year-end 2026.

And here is the hole. The most recent balance sheet in this dataset is 2025-12-31. There is no quarterly balance sheet in the file at all — bal_a contains three annual rows and nothing else. This dive cannot see the cash position at 2026-03-31 or 2026-06-30. Seven months have elapsed, during which the company has, on the run-rate above, consumed roughly $850M-$900M.

Two mitigants, both real. First, the company has demonstrated repeated access to capital: $377.09M of stock issued in FY2025, $959.13M in FY2024, $392.39M in FY2023, plus $244.22M of net debt raised in FY2025. Second, km_ttm reports cash per share of $9.632 which, against an implied ~212.6M shares, gives $2.048B — consistent with the 2025-12-31 figure and suggesting the TTM metric has not moved much, though we cannot date it precisely.

One data-quality note we will not paper over. The reported TTM enterprise value of $38.784B sits only $3.67M below the $38.788B market cap, implying net cash of essentially zero. That is inconsistent with $2.026B of liquidity against $158.70M of debt. The most likely explanation is that the vendor's EV nets only cash-and-equivalents (not the $1.642B short-term investment portfolio) against debt, using a more recent cash figure. We have therefore used the balance-sheet liquidity of $2.026B throughout and computed our own enterprise value of ~$36.921B ($38.788B market cap less $2.026B liquidity plus $0.159B debt), labelled as such.

The conclusion. On the arithmetic available, RVMD is roughly a year of runway from the last date we can see, burning at an accelerating rate, and needs capital — from an equity raise, a partnership, or an acquirer — within the medium-term horizon. Consensus models cumulative net losses of $1.495B (FY2026E) plus $1.167B (FY2027E) = $2.662B against $2.026B of last-reported liquidity. That gap is arithmetic, not opinion. The financing is not a risk; it is a scheduled event whose terms are unknown.

4. The knowledge base — deep on the drug, single-source, and one claim that argues against the price

7 tagged claims name Revolution Medicines. All bullish. Conviction 58-75. Dated 2025-08-21 through 2026-06-12. kb_claim_count: 7.

The critical limitation, stated first: all seven come from ONE tracked source (Biotech Hangout). Breadth is 1. There is no cross-source corroboration anywhere in the base — no second independent voice on this name. That is the single largest reason conviction is rated Moderate rather than High, and it is a materially different situation from a name carried by three or four independent thinkers.

The claims, verbatim and dated:

• 2025-08-21, conviction 65: "Revolution Medicines leads the KRAS-inhibitor revolution transforming previously untreatable pancreatic cancer."
• 2025-10-22, conviction 60: "Revolution Medicines' RM-6236 RAS drug for pancreatic cancer is genuinely innovative and a deserving CNPV pick; well-liked by investors."
• 2026-01-09, conviction 65: "Rumored Merck acquisition at $28-32B would be a rich EV/sales multiple; RevMed's panRAS inhibitor daraxonrasib is well ahead in phase 3 pancreatic with massive unmet need."
• 2026-01-09, conviction 60: "Next-gen RAS agents from RevMed and Merck show better efficacy and safety than first-generation KRAS drugs (Mirati/Amgen); powerful discovery engine."
• 2026-06-09, conviction 75: "Daraxonrasib is a significant advance in pancreatic cancer — overall survival 13.2 vs 6.7 months, better PFS/ORR; Revolution Medicine set the bar despite a real side-effect profile."
• 2026-06-12, conviction 72: "Revolution Medicines clearly leads in RAS inhibitors; its direct RAS inhibitor daraxonrasib should be approved almost any day now, cementing a leadership position in the market."
• 2026-06-12, conviction 58: "Tango's PRMT5 inhibitor combined with Revmed's direct RAS inhibitor showed a 90%+ response rate in MTAP-deleted pancreatic cancer; path forward is a frontline combination benefiting both."

Three things to extract, and the third is the one that drives the verdict.

First, the science lane is strong, recent and rising in conviction — from 65 (August 2025) to 75 (June 2026), with the most recent claims carrying the most specific efficacy data. The highest-conviction claim (75) is also the most quantitative.

Second, the lane is honest about the downside. The same 2026-06-09 claim that reports doubled median survival explicitly notes "a real side-effect profile." That is not a throwaway — tolerability determines duration of therapy, which determines revenue per patient, which is a first-order input into the $3.788B FY2029 consensus.

Third — and this is the crux — the only claim anchored to a PRICE argues the stock is expensive. On 2026-01-09, the tracked source described a rumoured Merck acquisition at $28-32B and called it "a rich EV/sales multiple." Today the market capitalisation is $38.788B.

Run the arithmetic. Against an implied ~212.6M shares, $28-32B is $131.70 to $150.52 per share. Today's price is $182.45 — 21.2% above the top of the rumoured range and 38.5% above the bottom. And an acquisition price includes a control premium; the market is now paying more than a strategic buyer was rumoured to be contemplating, without one.

That is our variant perception in a single fact. The tracked lane underwrites the drug and, in its one price-anchored statement, implicitly flags the valuation. We are taking both halves seriously, which is why the verdict is Hold rather than Buy.

Sector backdrop, labelled as theme-level (does NOT name RVMD):

• Biotech Hangout, 2026-01-23, conviction 80: "Pharma has a ~$90B revenue hole unfillable by pipeline; only ~1/16 covered last year, so M&A should be busier this year." — the structural reason a company like this gets acquired.
• Biotech Hangout, 2026-06-26, conviction 70: "Not getting ahead of ourselves — a perfect storm of permissive FDA, M&A, low rates and strong innovation; still a differentiated stock picker's market, not frothy."
• Biotech Hangout, 2026-07-10, conviction 66: "The new FDA is 'open for business' for orphan/rare disease approvals — probability of success has shifted massively right ... maybe swinging too far toward lowering the bar."
• The counterweight — Biotech Hangout, 2026-01-23, conviction 70, bearish: "FDA is erratic and tumultuous (Prasad-driven Atara Tab-cel CRL); regulatory dysfunction is underappreciated extraneous risk."
• Biotech Hangout, 2026-01-09, conviction 45: "AstraZeneca licensed Jacobio's panRAS inhibitor ($100M upfront, ~$2B milestones) despite limited public data, implying in-house data validated the RAS space." — validating for the class, and a reminder that competition is arriving.

5. Technicals — a 389% year, five percent off the high, one day before the print

• Price $182.45 (2026-08-03 close, -2.71% that session from $187.53). 52-week range $34.00-$194.56 (quote) / $34.70-$192.62 (tech).
• -5.28% from the all-time high, and the max_dd_from_peak reading over the window is also -5.28% — meaning there has been no meaningful correction to buy.
• +425.8% above the 52-week low. The 200-day average is $116.12 and the stock is 57.1% above it — a gap that measures how violent and how recent the re-rating has been.
• 50-day average $172.25, price +6.0% above. RSI 47.8 — neutral, not overbought. MACD +3.48 — positive.
• Relative performance: +30.8% (3-month), +88.2% (6-month), +389.5% (12-month) against SPY at +5.1% / +9.5% / +19.9%. This is a 4.9-fold move in a year.

Read: an enormous, largely completed re-rating with no drawdown available and a binary event tomorrow. RSI at 47.8 rather than 70-plus is the one constructive technical detail — the stock has consolidated sideways rather than gone parabolic into the print. Support is the 50-DMA at $172.25 (-5.6%), and then a very long gap to the 200-DMA at $116.12 (-36.4%).

Insider activity — modest and one-directional. The only records are director Sushil Patel on 2026-06-29: exercising 2,955 options at $37.54 and selling 4,158 shares in seven tranches between $183.17 and $190.55, leaving 23,078 held. That is exercise-and-sell into strength near the highs by one director. It is not a red flag at this scale, but it is the only insider signal in the file and it is a sale.

6. Valuation — priced in or room?

There is no price-to-earnings ratio: revenue is zero and earnings are negative. Everything below is scenario arithmetic on consensus revenue and EPS, using our computed enterprise value.

Our enterprise value: market cap $38.788B less liquidity $2.026B plus debt $0.159B = ~$36.921B. (We are not using the vendor's TTM EV of $38.784B — see the data-quality note in section 3.)

Read the dispersion, because it is the honest description of this security. The FY2030 revenue estimate spans $2.940B to $14.396B — a 4.9-fold range. FY2029 EPS spans $1.79 to $14.42. Coverage is deep by biotech standards (14-17 analysts on the near years) and the analysts still disagree by a factor of five about 2030. That is what a binary looks like when it is honestly modelled.

Street position: consensus PT $194.09 (+6.4%), median $195, high $235 (+28.8%), low $144 (-21.1%). Ratings 1 strong buy, 21 buy, 1 hold, 0 sell — near-unanimous. FMP's quantitative rating is C-, overall score 1, which is simply the screen's mechanical dislike of a pre-revenue balance sheet and carries no information here.

Synthos fair values — two independent anchors, blended:

Anchor A — consensus multiple. 10x FY2029E consensus revenue ($3.788B) = $37.88B EV, plus $2.026B liquidity less $0.159B debt = $39.75B equity value ÷ 212.6M shares = $186.95. Ten times forward sales is a normal multiple for a high-growth commercial-stage biotech. Caveat, stated: this applies a 2029 multiple at a 2026 price with no discount for three years of waiting or for the dilution certain to occur in between — it is a generous anchor.

Anchor B — strategic value. The $28-32B rumoured acquisition range (Biotech Hangout, 2026-01-09, conviction 65) ÷ 212.6M shares = $131.70 to $150.52 — and that range would have included a control premium.

• Bear ~$95 — 5x FY2029E consensus revenue ($3.788B) = $18.94B EV plus net liquidity = $97.87, rounded down to $95 for the dilution the burn makes certain. Triggered by a commercial disappointment, the FY2027 low case ($462.04M rather than $861.11M), or the side-effect profile the tracked lane flags limiting real-world use. -47.9%.
• Base ~$170 — the blend of Anchor A ($187) and Anchor B ($132-$151), leaning toward the consensus anchor because estimates have risen since the January acquisition rumour and because the June 2026 efficacy claims are materially more supportive than what was known then. -6.8% against spot.
• Bull ~$278 — two methods converge: 15x FY2029E consensus revenue = $276.04, and 25x FY2030E consensus EPS ($11.14) = $278.51. Requires the launch to execute, the combination path to expand the addressable population, and the multiple to hold. Above the Street high of $235. +52.4%.

Base sits 6.8% below spot. That is the verdict expressed arithmetically.

6a. What today's price assumes (the inversion)

At $182.45 and a ~$36.921B enterprise value, today's price assumes roughly:

• Daraxonrasib is approved and launches successfully in 2026, generating the $101.67M consensus FY2026 revenue. (Falsifiable at the 2026-08-05 print — consensus revenue is $1.773M for Q2, so essentially all of the FY2026 figure has to arrive in the second half.) Consensus-derived, 15 analysts. Note: the dataset does not confirm approval has occurred.
• Revenue reaches $1.873B by FY2028 and $3.788B by FY2029 — an eighteen-fold increase from FY2027's $861.11M over two years. (Falsifiable: the FY2027 and FY2028 annual prints. Consensus-derived, 17 and 14 analysts.)
• The company reaches profitability in FY2029 with EPS of $4.84, implying net income near $1.03B against FY2025's negative $1.131B. (Falsifiable: the annual prints. 10 EPS analysts.)
• The market keeps paying roughly 10x forward sales three years out, i.e. no de-rating as the story converts from promise to execution. (Falsifiable in the price.)
• The financing between here and profitability is not punitive. Consensus cumulative losses of $2.662B over FY2026-FY2027 against $2.026B of last-reported liquidity means a raise is arithmetically necessary; the price assumes it happens on non-dilutive-ish terms. (Falsifiable: the share count, which has already gone from 190.13M weighted diluted in FY2025 to an implied ~212.6M.)
• A strategic buyer would pay more than $38.79B — because at today's price, the rumoured $28-32B range is already 21.2% below the market. (Falsifiable by any actual transaction. This is the assumption doing the most work and the one with the least support in the tracked lane.)

The single most fragile assumption is the runway. Not because the company will run out — it has raised repeatedly and can raise again — but because this dive cannot see the current cash balance, the balance sheet in the file is seven months old, the burn accelerated in every one of the last nine quarters, and the terms of the necessary financing are unknown. Everything else in the price is a clinical or commercial question with a lot of analyst attention on it. The financing is arithmetic, imminent, and invisible in this data.

6b. The return bridge (why the multiple moves)

expected return ≈ revenue ramp + multiple drift − dilution

For a pre-revenue biotech the conventional bridge does not apply, so state the real one. There is no EPS growth term (EPS is negative until FY2029), no shareholder yield (no dividend, no buyback, and the share count is rising). The return decomposes into exactly three pieces:

• Revenue ramp: consensus takes revenue from $0 to $3.788B by FY2029. If delivered, this is the entire source of value.
• Multiple drift: today's ~9.7x FY2029E sales would, in a successful commercial biotech, typically compress toward 5-8x as growth matures. Our base case assumes it holds near 10x, which is already generous.
• Dilution: the certain negative. Consensus losses of $2.662B over two years against $2.026B of liquidity means shares get issued. Every 10% of dilution is roughly 10% off the per-share value.

So the bridge to our $170 base is: the full consensus revenue ramp delivered, the sales multiple held flat at ~10x, and a modest dilution haircut — netting to slightly BELOW today's price. Read that again, because it is the whole case: at $182.45 you are paying, today, for consensus to be right about 2029, with no discount for three years of waiting, no discount for the dilution in between, and no allowance for the multiple compressing. The thesis for buying here requires the multiple to expand or consensus to prove too low — and that is the fragile leg.

6c. Variant perception (where we differ, what would surprise)

• We agree with the near-unanimous Street on the science and disagree on the entry. Twenty-two of twenty-three analysts are positive and the consensus PT of $194.09 is only 6.4% above spot — which means even the bulls see limited near-term upside. Our $170 base is 12.4% below theirs, and the difference is entirely the discount we apply for dilution and for three years of waiting, which the 10x-forward-sales framing ignores.
• Our sharpest variant perception is the takeout anchor, and it comes from our own knowledge base. The tracked source that most strongly underwrites the drug also, on 2026-01-09, described a rumoured $28-32B acquisition as "a rich EV/sales multiple." At $38.79B, the market has moved 21.2% above the top of that range — without a bid, and without the control premium such a bid would carry. We think the M&A support under this stock is weaker than the near-unanimous ratings imply, precisely because the most-cited potential buyer's rumoured price is now below the market.
• We also think the side-effect profile is underweighted. The same claim that reports 13.2 versus 6.7 months of overall survival flags "a real side-effect profile." In oncology, tolerability drives duration of therapy, which drives revenue per patient — an input the $3.788B FY2029 consensus depends on and which no one is modelling publicly.
• Positive surprise that would force a repricing higher. The 2026-08-05 print confirming approval and a launch with product revenue above the $1.773M consensus, a cash balance above $1.5B, and a burn that has stopped accelerating. Beyond that, the Tango PRMT5 combination advancing to a registrational frontline study would be the largest single expansion of the opportunity in the tracked lane — a 90%-plus response rate in MTAP-deleted pancreatic cancer, if it holds, changes the addressable population rather than the market share. Either would move us toward the $278 bull case.
• Negative surprise that would force a repricing lower. A dilutive financing on poor terms, a launch slower than the $101.67M FY2026 consensus, a safety signal in any RAS programme (which hits the platform, not one asset), or credible competitive data from Merck or AstraZeneca — the tracked lane places both in the RAS space, and notes AstraZeneca paid $100M upfront plus ~$2B in milestones for Jacobio's pan-RAS inhibitor. Any of these opens the $95-$132 zone. The watchable number tomorrow is the cash balance.

7. Verdict, kill-criteria and the flip conditions

Hold. Existing holders hold; new money waits for the 2026-08-05 print and a real drawdown.

We want to be unambiguous about which half of this call is which. On the science we are constructive and the knowledge base supports us at conviction 58-75: Revolution Medicines leads the RAS field, daraxonrasib's reported overall survival of 13.2 versus 6.7 months in pancreatic cancer is a genuine advance in one of oncology's hardest indications, the Tango combination showed a 90%-plus response rate in an MTAP-deleted subgroup, and the pathway supports a franchise rather than a product. Twenty-two of twenty-three analysts agree, and consensus models $5.706B of revenue by FY2030. If the platform works, this is a very large company.

On the price we are not constructive, and three facts drive it. First, the stock is up 389.5% in twelve months, sits 5.3% below its all-time high with no drawdown at all in the technical window, and is 57.1% above its own 200-day average. Second, the $38.79B market capitalisation is 21.2% above the top of the $28-32B range a tracked source described in January as "a rich EV/sales multiple" for a Merck acquisition — the market has already paid past its own strategic-value anchor, without a bid and without a control premium. Third, and most immediately, the burn accelerated in every one of the last nine quarters to $453.82M in Q1 2026, against $2.026B of liquidity on a balance sheet dated 2025-12-31 that this dataset does not update — we cannot see the current cash position, and the print that reveals it lands tomorrow.

Our base fair value of $170 is 6.8% below spot. The Street's own consensus target of $194.09 is only 6.4% above it. Nobody, including the bulls, sees much room at this price on this date.

Pre-registered kill / do-not-add criteria:

• A dilutive financing on poor terms. Consensus losses of $2.662B over FY2026-FY2027 against $2.026B of last-reported liquidity make a raise arithmetically necessary; the terms determine how much of the upside accrues to today's holders.
• A launch materially below the $101.67M FY2026 consensus, or no product revenue appearing by the Q3 2026 report.
• Any safety signal in any RAS-pathway programme. This is a platform, so a class-level tolerability problem is existential rather than partial — and the tracked lane already flags "a real side-effect profile."
• Credible competitive data from Merck or AstraZeneca, both of which the knowledge base places in the RAS space, with AstraZeneca having paid $100M upfront plus ~$2B in milestones for a pan-RAS asset.
• Loss of the 200-day average ($116.12) — a 36% fall from here, but the gap between price and that average is exactly the measure of how far an unwind could run.

Pre-registered flip to Stage-In (start building for new money):

• A pullback to the $130-$150 zone — the per-share equivalent of the $28-32B rumoured acquisition range — on no fundamental deterioration. That is a price at which a strategic buyer was rumoured to be interested, which is a reasonable definition of downside support.
• OR the 2026-08-05 print delivering all three of: confirmed approval and product revenue above consensus, a cash balance above $1.5B, and a burn that has stopped accelerating. That combination removes the largest unknown in this dive and would justify paying up.
• OR the Tango PRMT5 combination advancing to a registrational frontline study, which expands the addressable population rather than the share of it.

Where RVMD fits in the Synthos Framework Portfolio. The speculative-biotech / precision-oncology sleeve, at 1-2% maximum for new money and only after the print. Existing positions built at much lower prices — the 52-week low is $34.70 — should be held, because the tracked lane is strong, rising in conviction, and specific, and because the asymmetry for a low-basis holder is entirely different from the asymmetry for a new buyer at $182.45. Note the portfolio logic: this is genuinely uncorrelated with everything else in this batch, and its risk is idiosyncratic and binary rather than macro — which is exactly why it should be sized small and never averaged up. Logged as a tracked Synthos call (Hold) as of 2026-08-04 at $182.45.

Single biggest risk: the accelerating burn against a balance sheet this dataset cannot see. Q1 2026 lost $453.82M — annualising near $1.8B — against $2.026B of liquidity measured seven months ago, with losses having risen in nine consecutive quarters and no quarterly balance sheet available anywhere in the file. Dilution is not a risk; it is a scheduled event on unknown terms.

Single most fragile assumption in the price: that a strategic buyer would pay more than $38.79B. The one price-anchored claim in our knowledge base — the $28-32B rumoured Merck range from 2026-01-09, characterised by the source as already "rich" — puts the market 21.2% above the top of it, without a bid and without the control premium a bid would include. The M&A floor that many holders believe sits under this stock is, on the only dated evidence we have, below the current price.

Provenance and disclosures

• Traceability: 7 tagged knowledge-base claims name Revolution Medicines (kb_claim_count: 7), all bullish, conviction 58-75, dated 2025-08-21, 2025-10-22, 2026-01-09 (x2), 2026-06-09, 2026-06-12 (x2). All seven come from a single tracked source (Biotech Hangout) — breadth 1, with no cross-source corroboration, which is the principal reason conviction is rated Moderate rather than High. Five theme-level biotech-sector claims (2026-01-23 x2, 2026-06-26, 2026-07-10, 2026-01-09 on AstraZeneca/Jacobio) are cited in section 4 and explicitly labelled as not naming RVMD, and include one bearish counterweight on regulatory unpredictability at conviction 70.
• Efficacy figures are CITATIONS, not verified trial data. The dataset contains no clinical trial file for this ticker. Every efficacy figure in this dive — the 13.2-versus-6.7-month overall survival, the 90%-plus MTAP-deleted response rate — is a verbatim quotation of a dated tracked-thinker statement, labelled as such throughout, and has not been verified against a trial readout or a label.
• Regulatory status is NOT confirmed by this dataset. A tracked claim dated 2026-06-12 stated that daraxonrasib "should be approved almost any day now", and consensus models $101.67M of FY2026 revenue on 15 analysts, implying the Street models a 2026 launch. The dataset contains no approval confirmation and this dive does not assert one.
• Data as-of: prices and quote 2026-08-03 close (FMP quote timestamp 2026-08-03 20:00 UTC) · income statement through Q1 2026 (2026-03-31, filed 2026-05-06) · balance sheet 2025-12-31 (FY2025) — SEVEN MONTHS STALE · cash flow FY2025 · analyst estimates, price targets, grades and earnings calendar last updated 2026-08-04 · knowledge-base search 2026-08-04.
• CRITICAL data gap: bal_a contains only three annual rows and no quarterly balance sheet whatsoever. There is no Q1 2026 or Q2 2026 balance sheet in this dataset, so the current cash position is unknown to this dive. All runway arithmetic in section 3 is anchored to 2025-12-31 and labelled accordingly. The 2026-08-05 print resolves this, which is why the verdict is Hold rather than a directional call.
• Enterprise-value note: the vendor's TTM enterprise value of $38.784B sits only $3.67M below the $38.788B market cap, implying essentially zero net cash — inconsistent with $2.026B of liquidity against $158.70M of debt, and most likely reflecting a calculation that nets only cash-and-equivalents rather than the $1.642B short-term investment portfolio. We have used our own computed EV of ~$36.921B (market cap less balance-sheet liquidity plus debt) throughout and labelled it.
• Other gaps: seg_geo is empty — the company does not report geographic segments. seg_prod contains only historical collaboration revenue (FY2020-FY2022, $29-43M a year, Sanofi-related) and nothing current. There is no product-level revenue disclosure. Estimate dispersion is extreme and is reported rather than smoothed: FY2030E revenue spans $2.940B to $14.396B (4.9x) and FY2029E EPS spans $1.79 to $14.42.
• Share count: FY2025 weighted diluted shares were 190.13M; the implied current count from market cap divided by price is ~212.6M, cross-checked by TTM cash per share of $9.632 against $2.048B. All per-share figures use 212.6M and are labelled as implied.
• Fair-value method: two independent anchors, blended. Anchor A — 10x FY2029E consensus revenue ($3.788B) plus net liquidity, divided by 212.6M shares = $186.95, explicitly noted as generous because it applies a 2029 multiple at a 2026 price with no discount for waiting or dilution. Anchor B — the $28-32B rumoured acquisition range (Biotech Hangout, 2026-01-09, conviction 65) divided by 212.6M shares = $131.70-$150.52. Base $170 is the blend, leaning to Anchor A. Bear $95 is 5x FY2029E revenue less a dilution haircut; bull $278 is the convergence of 15x FY2029E revenue ($276.04) and 25x FY2030E EPS ($278.51). Stated arithmetic, not a discounted cash flow.
• Timing caveat: this dive is written the day before the Q2 2026 print (2026-08-05) — deliberately, and the verdict is shaped by it. The result will materially change the picture, most of all on cash.
• Not investment advice. Independent research, educational and informational only, never personalised.
• Version: 2026-08-04-full.